Swedish agencies to trial Bioniche E. coli vaccine
19 April, 2013 by Dylan Bushell-EmblingSwedish government agencies will incorporate Bioniche’s (ASX:BNC) E. coli O157 cattle vaccine in its research into limiting human infection by verotoxigenic E. coli.
Novogen’s largest shareholder leaves board
19 April, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) non-executive director Josiah Austin has resigned to avoid having to fly from the US to Australia for monthly board meetings.
Starpharma secures dendrimer patents
18 April, 2013 by Dylan Bushell-EmblingStarpharma (ASX:SPL) has been granted three new US patents for its dendrimer drug delivery platform and will soon pick up a patent in China.
Pharma Patent Review releases draft report for comment
18 April, 2013The Draft Report of the Pharmaceutical Patent Review is now open for comment.
Mesoblast board gets a Rose
17 April, 2013Dr Eric Rose, the cardiovascular surgeon who performed the first successful paediatric heart transplant, has joined Mesoblast’s board of directors.
Delayed reaction
17 April, 2013 by Tim Dean2012 wasn’t the breakthrough year many were expecting for Australian biotechs, but 2013 could be.
Quarterly R&D tax credit payments one step closer
16 April, 2013The federal government has released the draft legislation, to provide the research and development (R&D) tax incentive through quarterly credits, for public comment.
Phosphagenics partner scores Indian coup
16 April, 2013 by Dylan Bushell-EmblingPhosphagenics’ (ASX:POH) Indian licensee has arranged to sell a diclofenac gel using TPM technology to Novartis India.
UWA licenses genetic drug tech to Sarepta
15 April, 2013 by Dylan Bushell-EmblingThe University of Western Australia has licensed technology covering a prospective treatment for severe muscle-wasting disease DMD to existing partner Sarepta.
UBI picks up Vic govt technology voucher
15 April, 2013 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) and six other companies have secured grants of up to $250K under the Victorian Government’s Technology Implementation Voucher program.
Alchemia SPP raises $2.75m
13 April, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has wrapped up a capital raising round with an oversubscribed SPP, securing a total of $12.95m to help fund its metastatic colorectal cancer trial.
Benitec appoints Kevin Buchi to board
12 April, 2013 by Dylan Bushell-Embling and Lauren DavisNew Benitec (ASX:BLT) board member Kevin Buchi said he was drawn to the company due to the potential of its trial-ready hepatitis C treatment candidate.
Mesoblast CEO wins pontifical council award
12 April, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB) CEO Silviu Itescu has been named the first recipient of the Pontifical Council for Culture and Stem for Life Foundation’s Key Innovation Award.
pSivida launches social media push
11 April, 2013 by Dylan Bushell-EmblingpSivida (ASX:PVA) has launched channels on each of the four major social networks to provide more outlets to communicate key information to investors.
Tax reform story not over for biotech industry
11 April, 2013Building on the success of the Research and Development (R&D) Tax Incentive, industry leaders are calling for further tax reform to provide incentives for innovative manufacturing and investment, according to the Biotechnology Industry Position Survey 2013.
